Genenta Science (NASDAQ: GNTA) Featured in Virtual Coverage of the 34th Annual Roth Conference
Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon(TM) is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (“HSPCs”) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon(TM), which is under investigation in a phase 1/2 clinical…